• Argent Biopharma (ASX:RGT) MGC Pharmaceuticals has officially rebranded to Argent BioPharma
  • Strategic renaming follows infusion of capital and an operational overhaul
  • Company looking to establish itself as a leader in polypharmacology


Special Report: MGC Pharmaceuticals has officially rebranded and restructure as Argent BioPharma in the culmination of an extensive capital and operational restructuring, incorporating significant American capital and operational revisions.

MGC Pharmaceuticals (ASX:MXC) officially rebranded to Argent Biopharma (ASX:RGT) following approval from shareholders for the strategic renaming on March 18.

The dual-listed company says it has also updated its name and ticker code on the London Stock Exchange (LSE) and advised shareholders their holdings will remain unaffected by the change, with existing share certificates remaining valid.

The company says the strategic renaming marks a pivotal milestone in the company’s journey, bolstered by a substantial infusion of capital and a comprehensive operational overhaul.


Embracing polypharmacology

Leveraging sophisticated methodologies such as polypharmacology and nanotechnology, RGT says it’s committed to advancing therapeutic efficacy.

The biotech is working to establish itself as a leader in polypharmacology, a cutting-edge approach aimed at simultaneously targeting multiple molecular pathways.

RGT says polypharmacology aims to address the complexities of multifaceted diseases, setting new benchmarks in drug development and therapeutic impact.

The company is placing special emphasis on its product range targeting immunology and neurology, using polypharmacology to innovate novel treatments.

Committed to addressing unmet medical needs, RGT aims to introduce new treatment every four years.

It’s key trademarked products include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer’s patients.

RGT says it also has additional therapies in the development pipeline.

The company says its European research hub is a key asset, playing a crucial role across the drug development continuum from conceptualisation to commercialisation.

Adhering to stringent EU GMP and GDP guidelines, RGT says the hub operates from two distinct manufacturing facilities.

The first one in Slovenia is dedicated to clinical trials and early access programs and the other in Malta is geared towards large-scale commercial production.


New name, new direction

CEO Roby Zomer says the rebranding is a key milestone for the company as it commits to advancement in biopharmaceuticals.

“As Argent BioPharma emerges from the restructured MGC Pharma, it embraces a new direction for the group and is well positioned in a new era in biopharmaceuticals, committed to providing accessible and impactful healthcare solutions on a global scale,” he says.

“This rebranding signifies our commitment to innovation and advancement in the biopharmaceutical landscape.

“We are excited to leverage our expertise in polypharmacology and nanotechnology to pioneer ground-breaking treatments, addressing unmet medical needs and driving positive change in global healthcare.”


This article was developed in collaboration with Argent BioPharma, a Stockhead advertiser at the time of publishing.  

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.